Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.

Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda SM, Wang X, Mehta JL, Bewtra M, Rustgi A, Hockstein N, Witt R, Masters G, Nam B, Smirnov D, Sepulveda MA, Gabrilovich DI.

Sci Immunol. 2016 Aug;1(2). pii: aaf8943. doi: 10.1126/sciimmunol.aaf8943. Epub 2016 Aug 5.

2.

Bone marrow myeloid cells in regulation of multiple myeloma progression.

Herlihy SE, Lin C, Nefedova Y.

Cancer Immunol Immunother. 2017 Aug;66(8):1007-1014. doi: 10.1007/s00262-017-1992-0. Epub 2017 Apr 4. Review.

PMID:
28378067
3.

Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells.

Tang CH, Zundell JA, Ranatunga S, Lin C, Nefedova Y, Del Valle JR, Hu CC.

Cancer Res. 2016 Apr 15;76(8):2137-52. doi: 10.1158/0008-5472.CAN-15-1885. Epub 2016 Mar 7.

4.

Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.

Pisklakova A, Grigson E, Ozerova M, Chen F, Sullivan DM, Nefedova Y.

Cancer Biol Ther. 2016 May 3;17(5):477-85. doi: 10.1080/15384047.2016.1156261. Epub 2016 Mar 2.

5.

Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.

Ramachandran IR, Condamine T, Lin C, Herlihy SE, Garfall A, Vogl DT, Gabrilovich DI, Nefedova Y.

Cancer Lett. 2016 Feb 1;371(1):117-24. doi: 10.1016/j.canlet.2015.10.040. Epub 2015 Nov 27.

6.

ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells.

Gabrilovich D, Nefedova Y.

Cancer Cell. 2015 Aug 10;28(2):147-9. doi: 10.1016/j.ccell.2015.07.007.

7.

Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma.

Bailey CK, Budina-Kolomets A, Murphy ME, Nefedova Y.

Cancer Biol Ther. 2015;16(9):1422-6. doi: 10.1080/15384047.2015.1071743. Epub 2015 Jul 15.

8.

Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner.

Grigson ER, Ozerova M, Pisklakova A, Liu H, Sullivan DM, Nefedova Y.

PLoS One. 2015 Jan 30;10(1):e0117693. doi: 10.1371/journal.pone.0117693. eCollection 2015.

9.

Regulation of dendritic cell differentiation in bone marrow during emergency myelopoiesis.

Liu H, Zhou J, Cheng P, Ramachandran I, Nefedova Y, Gabrilovich DI.

J Immunol. 2013 Aug 15;191(4):1916-26. doi: 10.4049/jimmunol.1300714. Epub 2013 Jul 5.

10.

Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.

Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T, Roth J, Gabrilovich D, Nefedova Y.

J Immunol. 2013 Apr 1;190(7):3815-23. doi: 10.4049/jimmunol.1203373. Epub 2013 Mar 4.

11.

Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.

Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, Sarnaik A, Horna P, Sotomayor E, Gabrilovich DI.

Nat Immunol. 2013 Mar;14(3):211-20. doi: 10.1038/ni.2526. Epub 2013 Jan 27.

12.

Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.

Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y.

Cell Oncol (Dordr). 2011 Dec;34(6):545-51. doi: 10.1007/s13402-011-0060-6. Epub 2011 Oct 1.

13.

Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.

Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI, Nefedova Y.

Mol Cancer Ther. 2010 Dec;9(12):3200-9. doi: 10.1158/1535-7163.MCT-10-0372.

14.

Lipid accumulation and dendritic cell dysfunction in cancer.

Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, Celis E, Lennox B, Knight SC, Padhya T, McCaffrey TV, McCaffrey JC, Antonia S, Fishman M, Ferris RL, Kagan VE, Gabrilovich DI.

Nat Med. 2010 Aug;16(8):880-6. doi: 10.1038/nm.2172. Epub 2010 Jul 11.

15.

Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.

Nefedova Y, Gabrilovich D.

Drug Resist Updat. 2008 Dec;11(6):210-8. doi: 10.1016/j.drup.2008.09.002. Epub 2008 Oct 31. Review.

16.

Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy.

Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI.

Blood. 2008 Feb 15;111(4):2220-9. Epub 2007 Nov 26.

17.

Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells.

Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI.

Cancer Res. 2007 Nov 15;67(22):11021-8. Erratum in: Cancer Res. 2008 Jan 15;68(2):626.

18.

Targeting of Jak/STAT pathway in antigen presenting cells in cancer.

Nefedova Y, Gabrilovich DI.

Curr Cancer Drug Targets. 2007 Feb;7(1):71-7. Review.

PMID:
17305479
19.

Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands.

Cheng P, Nefedova Y, Corzo CA, Gabrilovich DI.

Blood. 2007 Jan 15;109(2):507-15. Epub 2006 Sep 14.

Supplemental Content

Loading ...
Support Center